Augustine Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $108.0Mattributed |
|---|---|
| Latest round | series-a, $91.8M, 2025-06-01attributed |
| Founded | 2018 |
| Headquarters | Leuven |
| Industry | bio |
| Stage | series-a |
| Website | augustinetherapeutics.com |
Clinical-stage biotech developing selective HDAC6 inhibitors for neuromuscular, neurodegenerative and cardio-metabolic disease. Patients with Charcot-Marie-Tooth, ALS and related conditions are the initial focus. A novel non-hydroxamate, non-hydrazide chemotype preserves HDAC6's beneficial functions, making it suited to chronic dosing.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | series-a | $91.8M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $91.8M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $108.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | augustinetherapeutics.com, read 2026-05-02 |
| Description | self-reported | augustinetherapeutics.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.